Press releases and news about Genus from other sources

News releases

March 3, 2011

Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer

Genus Oncology, LLC, a clinical-stage company focused on commercializing novel drugs for treatment of cancer, announced it has received an Orphan Drug designation for its MUC1 targeting peptide, GO-203-2c, for the treatment of pancreatic cancer from the FDA's Office of Orphan Products Development. Full Story

February 15, 2011

Genus Oncology, LLC Announces Initiation of Phase 1 Trial of GO-203-2c in Patients with Solid Tumors

Genus Oncology, LLC, a clinical-stage company focused on commercializing novel drugs for treatment of cancer, announced it has successfully filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) and has dosed the first patient in a Phase I trial to test its lead compound, GO-203-2c, in patients with solid tumors. Full Story